Use of hospice at end of life is significantly influenced by physician characteristics
the ONA take:
The strongest known predictor of whether a patient will enroll in hospice care is the individual physician the patient sees, according to new research from Brigham and Women’s Hospital.
This factor outweighs other known factors, including geographic location, patient age, race, and comorbidities.
After controlling for other factors that predict hospice enrollment, the researchers found that patients were 27% more likely to enroll in hospice if they saw a physician in the top 10% of hospice use, compared with those who saw a physician in the bottom 10%. In addition, they found that a large number of cancer patients were seen by a relatively small group of physicians.
Study results also showed that regional factors, greater comorbidity, and physician specialty were significantly associated with the likelihood of hospice enrollment.
A new effect seen in this study was physicians associated with for profit hospitals were less likely to have patients enroll in hospice, compared with physicians with non-profit hospitals.
The strongest known predictor of whether a patient will enroll in hospice care is the individual physician the patient sees.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|